We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PANSS

News List

Cerevel surges on positive data for CVL-231 in schizophrenia trial, start of public offering firstwordpharma
June 30, 2021
Shares in Cerevel Therapeutics jumped as much as 136% Tuesday after the company reported "clinically meaningful and statistically significant" Phase Ib study results for CVL-231, a muscarinic M4-selective positive allosteric modulator .
Novel shows promise in Phase II schizophrenia trial europeanpharmaceuticalreview
February 26, 2021
KarXT significantly reduced both positive and negative of symptoms of schizophrenia without the common problematic side effects of current antipsychotic therapies.
Lundbeck craters as resistant schizophrenia drug fails phase III pharmaphorum
December 19, 2018
Danish drugmaker Lundbeck saw more than a quarter of the value wiped off its shares yesterday after its top pipeline prospect, a drug for schizophrenia, missed the mark in a phase III trial.....